Drugs by condition
Drugs approved for transthyretin amyloidosis
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
5
Still marketed, NDA or BLA
Drug classes
2
Novel drugs
4
New molecular entities and new biologics
In development
3
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for transthyretin amyloidosis.
- Attruby (Acoramidis Hydrochloride) · Bridgebio Pharma NovelOrphanNov 22, 2024
- Wainua (Autoinjector) (Eplontersen Sodium) · Astrazeneca Ab NovelOrphanDec 21, 2023
- Amvuttra (Vutrisiran Sodium) · Alnylam Pharms INC NovelOrphanJun 13, 2022
- Vyndamax (Tafamidis) · Foldrx Pharms OrphanMay 3, 2019
- Onpattro (Patisiran Sodium) · Alnylam Pharms INC NovelBreakthrough therapyPriority reviewOrphanAug 10, 2018
All approved drugs for transthyretin amyloidosis, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Transthyretin-directed RNA Interaction (1)
- Wainua (Autoinjector) Eplontersen Sodium · Astrazeneca Ab · 2023
Class not listed in FDA's data (4)
Drugs in development for transthyretin amyloidosis
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- ALXN2220Phase 34 trials
AstraZeneca · Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Transthyretin Amyloid Cardiomyopathy, Amyloid Transthyretin Cardiomyopathy
- NNC6019-0001Phase 33 trials
Novo Nordisk · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- NucresiranALN-TTRSC04Phase 32 trials
Alnylam Pharmaceuticals · Transthyretin Amyloidosis With Cardiomyopathy, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
1 discontinued brand-name drugs whose label still names it
- Vyndaqel Tafamidis Meglumine
More on transthyretin amyloidosis: recruiting trials · published research
Related in rare and genetic disease: Hereditary angioedema · Fabry disease · Gaucher disease · Pompe disease · Phenylketonuria (PKU) · Achondroplasia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.